Targeting ATG4 in Cancer Therapy
AbstractAutophagy is a lysosome-mediated degradation pathway that enables the degradation and recycling of cytoplasmic components to sustain metabolic homoeostasis. Recently, autophagy has been reported to have an astonishing number of connections to cancer, as tumor cells require proficient autophagy in response to metabolic and therapeutic stresses to sustain cell proliferation. Autophagy-related gene 4 (ATG4) is essential for autophagy by affecting autophagosome formation through processing full-length microtubule-associated protein 1A/1B-light chain 3 (pro-LC3) and lipidated LC3. An increasing amount of evidence suggests that ATG4B expression is elevated in certain types of cancer, implying that ATG4B is a potential anticancer target. In this review, we address the central roles of ATG4B in the autophagy machinery and in targeted cancer therapy. Specifically, we discuss how pharmacologically inhibiting ATG4B can benefit cancer therapies. View Full-Text
Share & Cite This Article
Fu, Y.; Huang, Z.; Hong, L.; Lu, J.-H.; Feng, D.; Yin, X.-M.; Li, M. Targeting ATG4 in Cancer Therapy. Cancers 2019, 11, 649.
Fu Y, Huang Z, Hong L, Lu J-H, Feng D, Yin X-M, Li M. Targeting ATG4 in Cancer Therapy. Cancers. 2019; 11(5):649.Chicago/Turabian Style
Fu, Yuanyuan; Huang, Zhiying; Hong, Liang; Lu, Jia-Hong; Feng, Du; Yin, Xiao-Ming; Li, Min. 2019. "Targeting ATG4 in Cancer Therapy." Cancers 11, no. 5: 649.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.